184 related articles for article (PubMed ID: 16681772)
21. Uterine smooth muscle tumors: utility of classification by proliferation, ploidy, and prognostic markers versus traditional histopathology.
Layfield LJ; Liu K; Dodge R; Barsky SH
Arch Pathol Lab Med; 2000 Feb; 124(2):221-7. PubMed ID: 10656730
[TBL] [Abstract][Full Text] [Related]
22. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
[TBL] [Abstract][Full Text] [Related]
23. Roles of Matrix Metalloproteinases 2 and 9 in Uterine Leiomyosarcoma.
Wang X; Li C; Lou L; Zhu H
Anticancer Res; 2024 Apr; 44(4):1465-1473. PubMed ID: 38537953
[TBL] [Abstract][Full Text] [Related]
24. Molecular differential analysis of uterine leiomyomas and leiomyosarcomas through weighted gene network and pathway tracing approaches.
Sahly NN; Banaganapalli B; Sahly AN; Aligiraigri AH; Nasser KK; Shinawi T; Mohammed A; Alamri AS; Bondagji N; Elango R; Shaik NA
Syst Biol Reprod Med; 2021 Jun; 67(3):209-220. PubMed ID: 33685300
[TBL] [Abstract][Full Text] [Related]
25. Human uterine leiomyoma cells: binding and growth responses to epidermal growth factor, platelet-derived growth factor, and insulin.
Fayed YM; Tsibris JC; Langenberg PW; Robertson AL
Lab Invest; 1989 Jan; 60(1):30-7. PubMed ID: 2536127
[TBL] [Abstract][Full Text] [Related]
26. The role of fibroblast growth factor 2 in patients with uterine smooth muscle tumors: an immunohistochemical study.
Bodner-Adler B; Mayerhofer K; Czerwenka K; Kimberger O; Koelbl H; Bodner K
Eur J Obstet Gynecol Reprod Biol; 2016 Dec; 207():62-67. PubMed ID: 27825029
[TBL] [Abstract][Full Text] [Related]
27. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis.
Bodner-Adler B; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
Gynecol Oncol; 2005 Jan; 96(1):62-6. PubMed ID: 15589581
[TBL] [Abstract][Full Text] [Related]
28. TOP2A copy number and TOP2A expression in uterine benign smooth muscle tumours and leiomyosarcoma.
Baiocchi G; Poliseli FL; De Brot L; Mantoan H; Schiavon BN; Faloppa CC; Vassallo J; Soares FA; Cunha IW
J Clin Pathol; 2016 Oct; 69(10):884-9. PubMed ID: 26994023
[TBL] [Abstract][Full Text] [Related]
29. Immunoexpression of p53 in cutaneous and subcutaneous leiomyosarcomas.
Fernandez-Flores A; Monteagudo C
Ann Diagn Pathol; 2016 Oct; 24():25-9. PubMed ID: 27649950
[TBL] [Abstract][Full Text] [Related]
30. Sleeping Beauty Transposon Mutagenesis Identifies Genes Driving the Initiation and Metastasis of Uterine Leiomyosarcoma.
Kodama M; Shimura H; Tien JC; Newberg JY; Kodama T; Wei Z; Rangel R; Yoshihara K; Kuruma A; Nakae A; Hashimoto K; Sawada K; Kimura T; Jenkins NA; Copeland NG
Cancer Res; 2021 Nov; 81(21):5413-5424. PubMed ID: 34475109
[TBL] [Abstract][Full Text] [Related]
31. Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways.
Cuppens T; Moisse M; Depreeuw J; Annibali D; Colas E; Gil-Moreno A; Huvila J; Carpén O; Zikán M; Matias-Guiu X; Moerman P; Croce S; Lambrechts D; Amant F
Int J Cancer; 2018 Mar; 142(6):1230-1243. PubMed ID: 29063609
[TBL] [Abstract][Full Text] [Related]
32. Expression of matrix metalloproteinases in patients with uterine smooth muscle tumors: an immunohistochemical analysis of MMP-1 and MMP-2 protein expression in leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner-Adler B; Bodner K; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):182-6. PubMed ID: 15051038
[TBL] [Abstract][Full Text] [Related]
33. Fascin expression in uterine smooth muscle tumors.
Kefeli M; Yildiz L; Kaya FC; Aydin O; Kandemir B
Int J Gynecol Pathol; 2009 Jul; 28(4):328-33. PubMed ID: 19483633
[TBL] [Abstract][Full Text] [Related]
34. The value of re-exploration in patients with inadvertently morcellated uterine sarcoma.
Oduyebo T; Rauh-Hain AJ; Meserve EE; Seidman MA; Hinchcliff E; George S; Quade B; Nucci MR; Del Carmen MG; Muto MG
Gynecol Oncol; 2014 Feb; 132(2):360-5. PubMed ID: 24296345
[TBL] [Abstract][Full Text] [Related]
35. Molecular cytogenetic analysis of uterine leiomyoma and leiomyosarcoma by comparative genomic hybridization.
Levy B; Mukherjee T; Hirschhorn K
Cancer Genet Cytogenet; 2000 Aug; 121(1):1-8. PubMed ID: 10958933
[TBL] [Abstract][Full Text] [Related]
36. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.
Farid M; Ong WS; Tan MH; Foo LS; Lim YK; Chia WK; Soh LT; Poon D; Lee MJ; Ho ZC; Jeevan R; Chin F; Teo M; Quek R
Am J Clin Oncol; 2013 Aug; 36(4):368-74. PubMed ID: 22772425
[TBL] [Abstract][Full Text] [Related]
37. EMMPRIN (CD147) Expression in Smooth Muscle Tumors of the Uterus.
Kefeli M; Yildiz L; Gun S; Ozen FZ; Karagoz F
Int J Gynecol Pathol; 2016 Jan; 35(1):1-7. PubMed ID: 26352545
[TBL] [Abstract][Full Text] [Related]
38. Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma.
Brewer Savannah KJ; Demicco EG; Lusby K; Ghadimi MP; Belousov R; Young E; Zhang Y; Huang KL; Lazar AJ; Hunt KK; Pollock RE; Creighton CJ; Anderson ML; Lev D
Clin Cancer Res; 2012 Sep; 18(17):4633-45. PubMed ID: 22821997
[TBL] [Abstract][Full Text] [Related]
39. The Role of Endometrial Biopsy in the Preoperative Detection of Uterine Leiomyosarcoma.
Hinchcliff EM; Esselen KM; Watkins JC; Oduyebo T; Rauh-Hain JA; Del Carmen MG; Quade BJ; Muto MG
J Minim Invasive Gynecol; 2016; 23(4):567-72. PubMed ID: 26851414
[TBL] [Abstract][Full Text] [Related]
40. Cutaneous leiomyomas and leiomyosarcomas: an immunohistochemical study with p53.
Fernandez-Flores A
Rom J Morphol Embryol; 2010; 51(2):295-8. PubMed ID: 20495746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
